

29 June 2026

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Reconfirming FY26 Guidance & Acquisition Completion

Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) ('Alcidion' or the 'Company') is pleased to provide a trading update for the financial year ending 30 June 2026 (FY26), including reconfirmation of FY26 full year guidance and confirmation of the completion of the acquisition of the business and assets of Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ (collectively, the 'Kyra flow products') from Telstra Health.

Highlights:

- FY26 guidance reconfirmed:
 - Revenue expected to exceed \$50M;
 - EBITDA expected to exceed \$5.0M; and
 - Operating cashflow expected to be broadly in-line with FY25 operating cashflow of \$5.8M
- On 29 June 2026, Alcidion completed the acquisition of the Kyra flow products business from Telstra Health as announced to the ASX on 18 May 2026, adding 33 customers (31 new customers) and further underpinning Alcidion's position as a leading provider of patient flow solutions in ANZ and the UK

Alcidion reconfirms its FY26 guidance based on financial performance, cash inflow and contracted revenue.

Alcidion CEO and Managing Director, Kate Quirke commented:

"Based on our performance to date, and across all key metrics, FY26 has been a record year for the business and given the nature of our long-term contracted revenue (which for many of our larger contracts extending out into the mid 2030's), we are well positioned for continued growth into the future".

"This quarter we signed a contract with UHSussex and have subsequently been paid for the material upfront license fee portion of the contract, thereby enabling us to reconfirm, with a high degree of confidence, our expected earnings for FY26."

"We are delighted to welcome the Kyra flow products, customers and staff to Alcidion and look forward to further building on our leading position in the Australian patient flow market. The initial reaction from customers has been very positive with our focus now shifting to ensure an efficient integration process coupled with the highest level of customer service. The transaction is immediately earnings accretive (pre synergies) with the ability to create future opportunities for Miya Precision and the Kyra customers."

"We look forward to maintaining a relationship with Telstra Health, to leverage the complimentary nature of our respective product suites. "

The Company anticipates announcing its Q4 FY26 Quarterly Activities Report and Appendix 4C on 23 July 2026.

ENDS

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relationsinvestor@alcidion.com**About Alcidion**

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver clinical decision support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets — Australia, New Zealand and the United Kingdom — serving hospitals and healthcare organisations at scale, with further geographical expansion planned.

With over 25 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2026